Department Of Hematology and Oncology
Benjamin Herzberg, MD

I am a board-certified medical oncologist specializing in the treatment of thoracic malignancies. I received my undergraduate degree from Princeton University, an MD from the combined Harvard Medical School and MIT Program in Health Sciences and Technology (HST), and an MSc in the History of Science and Medicine from Imperial College, London. I completed my internship and residency training in internal medicine at Massachusetts General Hospital, where I was a Stanbury Physician-Scientist trainee, and my fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center, where I was Chief Fellow.

I see patients with all types of thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, mesothelioma and thymoma. As someone whose own life was touched by cancer diagnoses, I work with a team of specialists to bring individual, compassionate care to each of my patients.

My research interests are in lung cancer and cancers with special difficulties repairing damage to their DNA. I develop clinical trials using novel agents targeting DNA repair, bringing these drugs directly to my patients in the clinic. My laboratory work aims to define new vulnerabilities in cancer cells which can be leveraged for more effective, less toxic therapy. This work has been recognized by several awards from the NIH and other organizations.

Clinical Studies Managed By This Investigator:
Condition Study Title
Cancer [ CLOSED ] Study of AMG510 in Subjects with Advanced Solid Tumors
Cancer Study of RP-3500 in Combination with PARP Inhibitor for Patients with Advanced Cancer
Cancer Study of IDE397 in Patients with Advanced Solid Tumors
Lung Cancer [ CLOSED ] Study of Berzosertib Compared to Chemotherapy for Patients with Non-Small Cell Lung Cancer
Cancer Study of ASP3082 in Patients with Advanced Cancer with a KRAS G12D Mutation
Cancer Study of RMC-6291 in Patients with Advanced Solid Tumors
Cancer Study of MRT-2359 in Patients with Solid Tumors
Cancer Study of RMC-6236 in Patients with Solid Tumors with a KRAS Mutation